Related Experiment Videos
Serum anticholinergic activity, white matter hyperintensities, and cognitive performance.
R D Nebes1, B G Pollock, C C Meltzer
1Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. nebesrd@upmc.edu
Neurology
|November 9, 2005
Summary
Anticholinergic medications worsen cognitive decline in elderly individuals with white matter hyperintensities (WMH). Higher serum anticholinergic activity (SAA) combined with increased WMH volume led to the most significant cognitive impairments.
Area of Science:
- Neurology
- Gerontology
- Pharmacology
Background:
- White matter hyperintensities (WMH) are common in the elderly and associated with cognitive impairment.
- Anticholinergic medications are frequently used by older adults and can affect cognition.
Purpose of the Study:
- To investigate if anticholinergic medication use exacerbates cognitive impairments in elderly individuals with WMH.
- To determine the relationship between serum anticholinergic activity (SAA) and WMH volume on cognitive function.
Main Methods:
- Assessed cognitive function in normal elderly subjects.
- Measured white matter hyperintensity (WMH) volume using neuroimaging.
- Quantified serum anticholinergic activity (SAA) levels.
Main Results:
- A synergistic interaction was observed between SAA and WMH volume.
- Cognitive decrements were most pronounced in individuals with both high SAA and significant WMH volume.
- Elderly individuals in the highest quartile of SAA showed the greatest cognitive decline with increasing WMH.
Conclusions:
- Anticholinergic medication exposure, indicated by SAA, significantly exacerbates cognitive impairments associated with WMH in the elderly.
- This highlights the importance of considering anticholinergic burden when assessing cognitive health in older adults with cerebrovascular changes.